AstraZeneca : AstraZeneca chercherait à se rapprocher de Gilead
>Ce serait le plus gros deal de l’histoire du secteur - Selon Bloomberg ce dimanche, AstraZeneca aurait sollicité Gilead le mois dernier en vue d’un rapprochement dans ce qui serait le plus gros deal pharma de l’histoire. AstraZeneca pèse 141 Md$ de capitalisation boursière et Gilead 96 Md$. Les revenus du nouvel ensemble dépasseraient les 53 Md$ (2021e) et surtout seraient quasi intégralement réalisés avec des médicaments de prescription, faisant d’AstraZeneca la plu...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.